Figure 4

c-FOXP3 recruits Treg cells in vitro and in vivo. (a) FACS analysis of Treg cells recruitment by FOXP3 overexpressed Panc-1, BxPC-3, and AsPC-1 cells for 24- h relative to empty vector-transfected cells, and Treg cells recruitment by FOXP3-interfered Panc-1, BxPC-3 and MIA PaCa-2 cells for 24- h relative to control groups. Representative results were shown. (b) Percentage of recruited CD4⁺CD25⁺FOXP3⁺Treg cells from peripheral blood mononuclear cells (PBMCs; mean±s.e.m., n=5; *P<0.05 by Student’s t-test). (c) Total numbers of recruited Treg cells from PBMCs (mean±s.e.m., n=5; *P<0.05 by Student’s t-test). (d) Experimental scheme for orthotropic pancreatic carcinoma model: mice were divided into two groups (n=5 per group). One was implanted with Panc-1-pLV-Control cells and the other was implanted with Panc-1-pLV-FOXP3 cells. Both groups received human PBMCs injection on days 1, 8, 15, 22, 29 and 36 through tail vein. Tumors were harvested at the sixth week. (e) FACS analysis of Treg cells recruitment into tumor microenvironment of both groups was measured. Representative results were shown; (mean±s.e.m., n=5; *P<0.05 by Student’s t-test).